Join Volition for a virtual investor event, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer, and Gael Forterre, Chief Commercial Officer, who will discuss the unmet medical need and current treatment landscape for patients with sepsis and septic shock.

The event will focus on Nu.Q^® NETs H3.1, a promising novel biomarker for early mortality and organ dysfunction in sepsis, and an independent predictor of the need for renal replacement therapy (RRT). Recently published results from a large-scale study indicate a potential clinical utility for risk stratification and early intervention in critically ill patients presenting with sepsis.

A live question and answer session will follow the formal presentations.